<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39397762</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0334</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Statistical methods in medical research</Title><ISOAbbreviation>Stat Methods Med Res</ISOAbbreviation></Journal><ArticleTitle>A seamless Phase I/II platform design with a time-to-event efficacy endpoint for potential COVID-19 therapies.</ArticleTitle><Pagination><StartPage>9622802241288348</StartPage><MedlinePgn>9622802241288348</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09622802241288348</ELocationID><Abstract><AbstractText>In the search for effective treatments for COVID-19, the initial emphasis has been on re-purposed treatments. To maximize the chances of finding successful treatments, novel treatments that have been developed for this disease in particular, are needed. In this article, we describe and evaluate the statistical design of the AGILE platform, an adaptive randomized seamless Phase I/II trial platform that seeks to quickly establish a safe range of doses and investigates treatments for potential efficacy. The bespoke Bayesian design (i) utilizes randomization during dose-finding, (ii) shares control arm information across the platform, and (iii) uses a time-to-event endpoint with a formal testing structure and error control for evaluation of potential efficacy. Both single-agent and combination treatments are considered. We find that the design can identify potential treatments that are safe and efficacious reliably with small to moderate sample sizes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaki</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1096-188X</Identifier><AffiliationInfo><Affiliation>Faculty for Informatics and Data Science, University Regensburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Biostatistics Unit, University of Cambridge, UK.</Affiliation><Identifier Source="RINGGOLD">2152</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnett</LastName><ForeName>Helen</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7466-7033</Identifier><AffiliationInfo><Affiliation>School of Mathematical Sciences, Lancaster University, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Titman</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Mathematical Sciences, Lancaster University, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozgunov</LastName><ForeName>Pavel</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6810-0284</Identifier><AffiliationInfo><Affiliation>MRC Biostatistics Unit, University of Cambridge, UK.</Affiliation><Identifier Source="RINGGOLD">2152</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stat Methods Med Res</MedlineTA><NlmUniqueID>9212457</NlmUniqueID><ISSNLinking>0962-2802</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adaptive platform trial</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">dose-escalation</Keyword><Keyword MajorTopicYN="N">randomized</Keyword><Keyword MajorTopicYN="N">seamless</Keyword><Keyword MajorTopicYN="N">time-to-improvement</Keyword></KeywordList><CoiStatement>Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39397762</ArticleId><ArticleId IdType="doi">10.1177/09622802241288348</ArticleId></ArticleIdList></PubmedData></PubmedArticle>